Are There New Medications For Managing Chronic Respiratory Conditions?

A medicine can acquire a use in another disease

The May 2025 Nucala prescribing information includes add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. That is a defined population, not all adults with COPD.

The same document has a separate severe-asthma indication with its own age and phenotype requirements. A medicine shared between conditions does not make the diagnoses or treatment plans interchangeable. Ask which indication is being considered and what assessment establishes that it fits.

A newer medicine still has a specific treatment job

Exdensur’s December 2025 US label describes add-on maintenance treatment for severe eosinophilic asthma in adults and children aged 12 and older. It is not for relief of acute bronchospasm or status asthmaticus.

That limitation separates an ongoing treatment option from attack care. Its label also warns against abruptly discontinuing corticosteroids when treatment begins. A newer maintenance option is not permission to abandon the existing plan or choose your own transition.

Additional evidence does not always broaden the indication

FDA’s corrected Airsupra supplement letter, effective September 15, 2025, describes adding BATURA trial results to the prescribing information. It says the indication remained unchanged: as-needed treatment or prevention of bronchoconstriction and reduction of exacerbation risk in asthma patients aged 18 and older.

That is an evidence update, not an expanded pediatric indication. When reading a headline, check whether the change concerns a trial result, a newly approved use or something still being studied. None of those phrases alone tells you to change an inhaler.

Connect the development to an unresolved care need

UK asthma guidance recommends assessing reasons for poor control and explaining inhaler treatments. A new-drug discussion should still include symptoms, device use and difficulties following the current arrangement. It is not a substitute for that assessment.

The Nucala and Exdensur labels include important safety warnings, including hypersensitivity reactions. Ask what benefit is expected for your particular problem, which risks matter and how response will be reviewed. Discuss practical access and who coordinates any authorized change.

These are selected dated US examples, not a complete list of the newest 2026 options. Local approval, current full prescribing information and an individual clinical assessment determine whether a development is relevant to you.